Revolutionizing dementia care: Discover how portable, AI-driven MRI systems are breaking barriers in Alzheimer’s diagnosis ... the progressive pre-symptomatic stage of AD lasts between 10 ...

Atrophy of medial temporal structures is now considered to be a valid diagnostic marker at the mild cognitive impairment stage ... Alzheimer neurodegeneration, has been established. Finally, MRI ...

Oct 29 (Reuters) - Coya Therapeutics (COYA.O), opens new tab said on Tuesday its experimental Alzheimer's drug was ... Alzheimer's disease enrolled in a small, mid-stage trial.

After spending decades fixated on a single hypothesis, Alzheimer’s researchers are ... brain with magnetic pulses — got a boost when mid-stage trial data was presented Thursday.

On Thursday, Vigil Neuroscience Inc. (NASDAQ:VIGL) released data from its completed Phase 1 trial evaluating VG-3927 as a potential treatment for Alzheimer’s disease. Demonstrated a favorable ...

Inc. ALEC were down 35.1% on Nov. 26 after the company announced data from a mid-stage study that evaluated its pipeline candidate, AL002, for treating individuals with early Alzheimer’s disease ...

M. Thompson). Brain atrophy detected by high-resolution MRI is correlated with both tau deposition and neuropsychological deficits, and is a valid marker of Alzheimer disease (AD) and its ...